6-K - NovaBridge Biosciences (0001778016) (Filer)

6-K - NovaBridge Biosciences (0001778016) (Filer)

6-K - NovaBridge Biosciences (0001778016) (Filer)

6-K - NovaBridge Biosciences (0001778016) (Filer)

6-K - NovaBridge Biosciences (0001778016) (Filer)

6-K - NovaBridge Biosciences (0001778016) (Filer)

6-K - NovaBridge Biosciences (0001778016) (Filer)

ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that Fu Wei, Executive Chairman of the Board, intends to purchase up to $5,000,000 of the Company's ADSs in open market transactions. The purchases started on January 15, 2026 and are ongoing as of the date of this press release. As the planned purchases are to be executed by Fu Wei via his controlled entity, NovaBridge cannot guarantee the number of ADSs to be purchased or the time frame in which the ADSs will be bought in the open market. "2025 was a defining yea

Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ -- Equity Insider News Commentary – The precision medicine sector is undergoing a structural realignment toward platform-based biologics, as the market prepares to surge from $138 billion this year to over $537 billion by 2035[1]. This shift marks the end of "one-size-fits-all" treatments, as investors rotate capital into modular systems designed to hunt multiple cancer targets at once. This secular transition is creating massive opportunities for specialized platforms that can scale across high-prevalence killers like lung, breast, and pancreatic cancers, led by GT Biopharma, Inc. (NASDAQ:GTBP), ImmunityBio (NA

Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and chemotherapy (mFOLFOX6) in 1L HER2-negative, metastatic gastric cancer patients, with 77% ORR observed at 8 mg/kg and 73% ORR observed at 12 mg/kg, across a wide range of PD-L1 and CLDN18.2 expression levelsThe median PFS was 16.9 months at 8 mg/kg; 12 mg/kg is immature with approximately 4-month shorter median follow-up; data will be updated in 2026Six-month landmark PFS was 73% for 8 mg/kg, and 91% for 12 mg/kg cohortsCombination was well tolerated; safety is comparable to the current standard of care treatmentData demonstrate that givastomig is a potential best-in-class C

NovaBridge Also Included in the Highly Regarded Nasdaq Biotech Index, Emphasizing its Position as an Industry Leader Opening the first trading session of the New Year marks an excellent beginning to 2026 for NovaBridgeInclusion in the Nasdaq Biotech Index (NBI) enhances NovaBridge's visibility and emphasizes the Company's position as an industry leader ROCKVILLE, Md., Dec. 30, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced Fu Wei, Executive Chairman of NovaBridge, will ring the Nasdaq Opening Bell on Friday, January 2, 2026, along wit

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistanceThe study achieved its objective, as the new Q6W extended dosing interval produced encouraging anti-tumor efficacy and immunological data in prior immune-oncology refractory or relapsed patients including anti-PD- (L)1 checkpoint inhibitor, with improved safety, compared to the prior Q2W scheduleThe poster includes positive immunological data on CD8+ cell proliferation and memory T-cell activation ROCKVILLE, Md., Dec.

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistanceThe Phase 1 ragistomig study achieved its objective, as the new Q6W extended dosing interval produced strong anti-tumor efficacy in PD-L1-non-responders, with an improved safety profileThe interim results, including immunological data on CD8+ cell proliferation and memory T-cell activation, are expected to be presented in a poster session at ESMO-IO on December 10, 2025 ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa

Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and chemotherapy (mFOLFOX6) in 1L HER2-negative, metastatic gastric cancer patients, with 77% ORR observed at 8 mg/kg and 73% ORR observed at 12 mg/kg, across a wide range of PD-L1 and CLDN18.2 expression levelsThe median PFS was 16.9 months at 8 mg/kg; 12 mg/kg is immature with approximately 4-month shorter median follow-up; data will be updated in 2026Six-month landmark PFS was 73% for 8 mg/kg, and 91% for 12 mg/kg cohortsCombination was well tolerated; safety is comparable to the current standard of care treatmentData demonstrate that givastomig is a potential best-in-class C

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa